Mucosis B.V. Receives Financial Support From The Dutch Government For Its Syngem® Program
5/22/2014 9:44:29 AM
Groningen, the Netherlands, May 22, 2014 / B3C newswire / - Biotechnology company Mucosis B.V. today announced that it has received an innovation credit line of up to €5 million from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs.
Mucosis will use these funds to further advance the clinical development of its proprietary SynGEM® prefusion F RSV vaccine candidate through human proof-of-concept studies. These studies aim to demonstrate both safety and protection against a challenge with RSV in healthy volunteers.
"We are delighted to have the support of the Dutch government in such an important disease area. Combined with our recently announced strategic partnership with BCHT of China and new investment round, we have now raised over €10 million in the first half of 2014. Advancing the SynGEM® program to human clinical trials through these funds will create a substantial company value inflection point in the near term", said Thomas Johnston, CEO of Mucosis. "Additionally, we see this significant funding as a further validation of our clinical-stage Mimopath® platform and its potential to combat the most challenging of infectious diseases.”
Mucosis B.V. is a clinical-stage Dutch biotechnology company with a proprietary platform technology, Mimopath®, on which it develops novel vaccines using various routes of administration including those that provide additional protection in the mucosa, the site where over 90% of pathogens enter the human body. Mucosis’s lead product is SynGEM®, a stabilized prefusion F protein recombinant vaccine to prevent RSV infection in various target groups. In addition, the company has developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria and FluGEM®, a vaccine to prevent influenza which served as a successful Mimopath® platform proof of concept through human clinical testing.
About Mimopath® technology
The Mimopath® technology is based on Lactococcus lactis, a Generally Recognized As Safe (GRAS) bacterium commonly used in the food industry. Mucosis has developed a robust proprietary technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be covered with antigens from viral, bacterial, parasitic or tumor origin. BLP-based vaccines are particularly suitable to administer into the nose or mouth, without the need for a needle. Such mucosal vaccines have been shown to raise protective immunity by activation of both the innate and the adaptive immune system.
SynGEM®, Mucosis’s lead vaccine candidate that is currently completing preclinical studies, is being developed in cooperation with corporate, governmental and non-governmental partners across the globe. SynGEM® is designed to prevent infections with Respiratory Syncytial Virus (RSV), which affect over 60 million people worldwide ranging from the very young to the elderly with more than one million hospitalizations and 160,000 deaths annually. The unique stabilized RSV prefusion F protein in SynGEM® displays the epitopes thought to be most important for optimal virus neutralization and is suitable for use in different formulations and administration routes to efficiently address various target groups. An RSV vaccine does not yet exist.
+31 (50) 8200050
Help employers find you! Check out all the jobs and post your resume.
comments powered by